Peginterferon beta-1a - Biologic Drug Details

Summary for peginterferon beta-1a

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for peginterferon beta-1a

Recent Clinical Trials for peginterferon beta-1a

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Peking University People's Hospital	EARLY_PHASE1
Xiamen Humanity Hospital	NA
Xiamen Hospital of Traditional Chinese Medicine	NA

See all peginterferon beta-1a clinical trials

Pharmacology for peginterferon beta-1a

Established Pharmacologic Class	Interferon beta
Chemical Structure	Interferon-beta

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for peginterferon beta-1a Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for peginterferon beta-1a Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biogen Inc.	PLEGRIDY	peginterferon beta-1a	Injection	125499		2024-03-16	DrugPatentWatch analysis and company disclosures
Biogen Inc.	PLEGRIDY	peginterferon beta-1a	Injection	125499		2024-07-16	DrugPatentWatch analysis and company disclosures
Biogen Inc.	PLEGRIDY	peginterferon beta-1a	Injection	125499		2031-09-12	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for peginterferon beta-1a Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biogen Inc.	PLEGRIDY	peginterferon beta-1a	Injection	125499		2034-01-08	Patent claims search
Biogen Inc.	PLEGRIDY	peginterferon beta-1a	Injection	125499		2036-10-04	Patent claims search
Biogen Inc.	PLEGRIDY	peginterferon beta-1a	Injection	125499		2038-08-23	Patent claims search

International Patents for peginterferon beta-1a

Country	Patent Number	Estimated Expiration
Hong Kong	1143553
Cyprus	2016027
Eurasian Patent Organization	201070773

Supplementary Protection Certificates for peginterferon beta-1a

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
286 50007-2016	Slovakia		PRODUCT NAME: PEGINTERFERON BETA-1A; REGISTRATION NO/DATE: EU/1/14/934 20140723
300826	Netherlands		PRODUCT NAME: PEGINTERFERON BETA-1A; REGISTRATION NO/DATE: EU/1/14/934 20140723
590	Finland

Market Dynamics and Financial Trajectory for Peginterferon Beta-1a

Last updated: February 20, 2026

Peginterferon beta-1a is a biologic used primarily in the treatment of multiple sclerosis (MS). It is marketed under brand names such as Plegridy by Biogen. The following analysis assesses the drug's current market position, competitive landscape, commercialization strategies, and financial prospects.

Market Penetration and Adoption

Peginterferon beta-1a received FDA approval in August 2014 and EMA approval in January 2015 for relapsing forms of multiple sclerosis. Since launch, it has established a moderate market share within the MS biologic segment. Its on-label benefit of dosing every two weeks offers a dosing advantage over traditional interferons, which require weekly or twice-weekly administration.

In 2022, Pegridy’s sales worldwide approached $700 million, with North America representing approximately 80% of revenue[1]. Market uptake reflects acceptance among neurologists, especially those preferring extended dosing intervals.

Competitive Positioning

Major competitors include:

• Avonex (Biogen): Weekly intramuscular interferon beta-1a
• Rebif (Eli Lilly): Thrice-weekly subcutaneous interferon beta-1a
• Plegridy (Biogen): Biweekly subcutaneous interferon beta-1a
• Oral agents: Dimethyl fumarate, fingolimod, and ozanimod

Peginterferon beta-1a's biweekly dosing provides a differentiation point against weekly or thrice-weekly comparators. However, oral segment's rapid growth and patient preference for oral therapy limit biologic market share expansion.

Market Challenges

1. Line of Therapy Trends: Increased adoption of oral agents and S1P receptor modulators reduces reliance on injectable interferons.
2. Side-Effect Profiles: Similar tolerability to other interferons; adverse events including flu-like symptoms remain common.
3. Pricing Pressures: Payer reimbursement struggles due to high costs relative to oral therapies.

Revenue Trends and Forecasts

Historical revenue data:

Year	Revenue (USD millions)	Year-over-Year Change
2019	600	-
2020	650	+8%
2021	680	+4.6%
2022	700	+2.9%

Forecasts estimate a compound annual growth rate (CAGR) of 2-3% through 2027, driven by continued uptake in established markets and potential expansion into emerging markets[2].

Regulatory and Pricing Developments

Regulatory agencies maintain strict pricing controls, especially in Europe. Value-based pricing negotiations may suppress future price increases. Biogen’s partnership with payers has involved discounts and patient support programs to improve market penetration.

R&D and Pipeline Outlook

Biogen explores next-generation interferons with improved safety profiles. No significant pipeline enhancements for peginterferon beta-1a are publicly disclosed, indicating reliance on current launch and market share strategies.

---

Key Takeaways

• Peginterferon beta-1a maintains a niche position in MS biologics, with a stable revenue base primarily in North America.
• Market share growth is limited by the rising popularity of oral therapies, compelling pricing pressure.
• Revenue growth remains modest, with projections indicating low double-digit growth over the next five years.
• Competition and evolving treatment paradigms constrain long-term upside unless new formulations or indications emerge.
• The biologic faces ongoing reimbursement challenges in mature markets.

---

FAQs

Q1: What factors inhibit significant growth for peginterferon beta-1a?
A1: Competition from oral MS therapies, patient preference for oral over injectable treatments, margin pressures, and increasing regulatory scrutiny on pricing.

Q2: How does peginterferon beta-1a compare in efficacy vs. other interferons?
A2: Its efficacy is comparable to other interferons for relapsing MS, with no major clinical superiority but benefits include extended dosing intervals.

Q3: What markets are most promising for expansion?
A3: Emerging markets with growing healthcare access and increasing MS diagnosis prevalence present opportunities, despite price sensitivity challenges.

Q4: Will pipeline development influence peginterferon beta-1a's market?
A4: Current pipeline activity does not focus on peglinterferon beta-1a, suggesting future growth depends on current formulation's performance and market trends.

Q5: How does biosimilar competition factor in?
A5: As biosimilars for interferons emerge, pricing pressure will intensify, potentially shrinking profit margins unless barriers to biosimilar entry are managed.

---

References

[1] Biogen Annual Report 2022. (2023).
[2] Evaluate Pharma. (2023). MS biologic market forecast.